Orencia gains JIA indication

The FDA has approved the use of Orencia (abatacept, from Bristol-Myers Squibb) for reducing signs and symptoms of moderately-to-severely active polyarticular juvenile idiopathic arthritis (JIA) in pediatric patients ≥6 years of age. This approval was based on a clinical study of children 6 to 17 years of age which showed a significant delay in disease flare and fewer disease flares while receiving Orencia when compared to placebo.

The FDA has also updated the adult rheumatoid arthritis indication by removing the requirement that patients must first fail at least one disease-modifying anti-rheumatic drug (DMARD) before initiating therapy with Orencia.

For more information call (800) ORENCIA or visit www.orencia.com.